The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

por Novotny-Diermayr, V, Hart, S, Goh, K C, Cheong, A, Ong, L-C, Hentze, H, Pasha, M K, Jayaraman, R, Ethirajulu, K, Wood, J M
Publicado 2012